Study of rare gynecological cancers using advanced testing
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial is collecting tissue and blood samples from people with rare gynecological cancers, such as unusual ovarian tumors, uterine sarcomas, or vulvar cancer. The goal is to use advanced lab tests (called multi-omics) to learn more about these cancers and improve treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with a non-epithelial ovarian tumor, a uterine sarcoma, or vulvar cancer.
- You do not have an active HIV, hepatitis B, or hepatitis C infection.
- You do not have another type of cancer at the same time.
- Your cancer type is not a common or non-rare form of gynecological cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses advanced testing (molecular profiling and imaging) to better understand cancers and help guide treatment. It is for people with certain advanced cancers who have not yet had immunotherapy or targeted therapy.
This study is watching and collecting data from patients with rare gynecologic tumors. It uses special tests on your tumor samples to learn more about these cancers, which may help find better treatments in the future.
This study is looking at people with rare cancers affecting the female reproductive system. It may help researchers learn more about how these cancers behave and how best to follow patients over time.
This study looks at tumor tissue and blood samples to find biological “markers” in people with gynecologic cancers. It may help researchers understand disease better and could guide future, more personalized treatments.
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
Hear when a new Uterine Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.